Back

Trends, Collaborations and Technologies Revolutionizing Clinical trials.

Virtual - Zoom  
Wednesday, March 29, 2023 12:00 PM - 1:00 PM   Add to Calendar Eastern Standard Time

Join us as our panel discusses the changes in the clinical trials landscape. Our host Dr MaryAnne Rizk will lead the conversation with our guest speakers: Caroline Redeker, SVP, Corporate Development, Advanced Clinical; Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology IDC; Jessica Branning, CEO My Memory Clinic Site Network; Kathrin Schoenborn-Sobolewski Start-up Advisor former Merck Group Executive Trends: Through increased use of AI data, decentralization and digitalization, we can develop new treatments faster than ever before, with the confidence that they will safely and effectively treat the populations they are intended to help. Technology is modernizing the rapid pace to accelerate drug development and is shifting the paradigm, per the FDA, “Decentralized Clinical Trials (DCT) hold promise to reduce patient and sponsor burden and increase accrual and retention of a more diverse trial population”. Technologies: Decentralization improves speed by accelerating enrollment (which can account for 60% of the total time of the trial and 80% of trial failures) and improves patient retention. By removing the barrier of geography, decentralization allows patients access to clinical research, regardless of how far they live from a clinic. By broadening the diversity of participants, we can produce data that is reflective of the population affected by the condition and improve scientific reliability. Collaboration: With an estimate of 70% of life sciences using digital ecosystems, according to a 2022 IDC report, sponsors, CROs, sites and technology providers are collaborating in new ways to embrace innovation that yield demonstrated value for patients, sites and sponsors. Innovating with new data, decentralized and digitalization options creates new possibilities to accelerate effective therapies to patients faster, but who are the new ecosystem of collaborators to work with these new techniques.

HBA Global presents

Trends, Collaborations and Technologies Revolutionizing Clinical trials.

Date and time
Wednesday, 29 March
12:00PM - 01:00PM EST
Location
Virtual - Zoom

Event Contact
De Scacchetti
+1 (201) 803-7905
Competencies
11. Fosters innovation

Join us as our panel discusses the changes in the clinical trials landscape. Our host Dr MaryAnne Rizk will lead the conversation with our guest speakers: Caroline Redeker, SVP, Corporate Development, Advanced Clinical; Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology IDC; Jessica Branning, CEO My Memory Clinic Site Network; Kathrin Schoenborn-Sobolewski, Start-up Advisor former Merck Group Executive.

Trends: Through increased use of AI data, decentralization and digitalization, we can develop new treatments faster than ever before, with the confidence that they will safely and effectively treat the populations they are intended to help. Technology is modernizing the rapid pace to accelerate drug development and is shifting the paradigm, per the FDA, “Decentralized Clinical Trials (DCT) hold promise to reduce patient and sponsor burden and increase accrual and retention of a more diverse trial population”.

Technologies: Decentralization improves speed by accelerating enrollment (which can account for 60% of the total time of the trial and 80% of trial failures) and improves patient retention. By removing the barrier of geography, decentralization allows patients access to clinical research, regardless of how far they live from a clinic. By broadening the diversity of participants, we can produce data that is reflective of the population affected by the condition and improve scientific reliability.

Collaboration: With an estimate of 70% of life sciences using digital ecosystems, according to a 2022 IDC report, sponsors, CROs, sites and technology providers are collaborating in new ways to embrace innovation that yield demonstrated value for patients, sites and sponsors. Innovating with new data, decentralized and digitalization options creates new possibilities to accelerate effective therapies to patients faster, but who are the new ecosystem of collaborators to work with these new techniques.


Registration information
Event is open to: HBA Members and Non-members

Cancellations/refunds
This event is refundable, requests must be submitted in writing to events@hbanet.org by 26 March 2023

Featured Speakers

Jessica  Branning
CEO and Founder
Nimita  Limaye
Research VP, Life Sciences R&D Strategy and Technology, IDC
International Data Corporation
Caroline  Redeker
Senior Vice President, Corporate Development
Advanced Clinical
MaryAnne  Rizk
Digital Health Board Exec
Kathrin  Schoenborn-Sobolewski
Investor & Start-up Advisor, Non-Executive Director

Registration information

The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

 Price LevelRegular
Collapse group

Registration: Regular Registration
 Member$10.00
 Member - Euro€9.00
 Non-Member$20.00
 Non-Member - Euro€18.00

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.